Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy.

@article{Jafri2010BaselineAO,
  title={Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy.},
  author={Haseeb Jafri and Alawi Alsheikh-ali and Richard H Karas},
  journal={Journal of the American College of Cardiology},
  year={2010},
  volume={55 25},
  pages={2846-54}
}
OBJECTIVES We sought to examine the relationship between high-density lipoprotein cholesterol (HDL-C) levels and the risk of the development of cancer in large randomized controlled trials (RCTs) of lipid-altering interventions. BACKGROUND Epidemiologic data demonstrate an inverse relationship between serum total cholesterol levels and incident cancer. We recently reported that lower levels of low-density lipoprotein cholesterol are associated with a significantly higher risk of incident… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 18 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Primary prevention of cardiovascular disease with pravastatin in Japan ( MEGA Study ) : a prospective randomised controlled trial

  • J Kjekshus, E Apetrei, V Barrios
  • Lancet
  • 2006

Similar Papers

Loading similar papers…